NYSE:GKOS - Glaukos Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Glaukos Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $57.09 -0.56 (-0.97 %) (As of 01/27/2020 02:08 PM ET) Add Compare Today's Range$56.50Now: $57.09▼$57.5150-Day Range$54.19MA: $56.74▼$59.9552-Week Range$53.19Now: $57.09▼$84.65Volume6,374 shsAverage Volume354,008 shsMarket Capitalization$2.08 billionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:GKOS Previous Symbol CUSIPN/A CIK1192448 Webhttp://www.glaukos.com/ Phone949-367-9600Debt Debt-to-Equity Ratio0.42 Current Ratio6.32 Quick Ratio5.94Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$181.28 million Price / Sales11.46 Cash FlowN/A Price / Cash FlowN/A Book Value$4.98 per share Price / Book11.46Profitability EPS (Most Recent Fiscal Year)($0.37) Net Income$-12,950,000.00 Net Margins-8.60% Return on Equity-4.01% Return on Assets-2.83%Miscellaneous Employees437 Outstanding Shares36,400,000Market Cap$2.08 billion Next Earnings Date2/26/2020 (Estimated) OptionableOptionable Receive GKOS News and Ratings via Email Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. GKOS Rates by TradingView Glaukos (NYSE:GKOS) Frequently Asked Questions What is Glaukos' stock symbol? Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS." How were Glaukos' earnings last quarter? Glaukos Corp (NYSE:GKOS) announced its earnings results on Wednesday, November, 6th. The medical instruments supplier reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.07. The medical instruments supplier earned $58.51 million during the quarter, compared to analysts' expectations of $56.96 million. Glaukos had a negative return on equity of 4.01% and a negative net margin of 8.60%. Glaukos's revenue for the quarter was up 33.2% on a year-over-year basis. During the same period last year, the business posted ($0.17) EPS. View Glaukos' Earnings History. When is Glaukos' next earnings date? Glaukos is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Glaukos. What price target have analysts set for GKOS? 9 Wall Street analysts have issued 1-year price objectives for Glaukos' stock. Their forecasts range from $58.00 to $80.00. On average, they expect Glaukos' share price to reach $68.89 in the next year. This suggests a possible upside of 20.7% from the stock's current price. View Analyst Price Targets for Glaukos. What is the consensus analysts' recommendation for Glaukos? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Glaukos. What are Wall Street analysts saying about Glaukos stock? Here are some recent quotes from research analysts about Glaukos stock: 1. According to Zacks Investment Research, "Glaukos is currently progressing with the U.S. commercial rollout of its next-generation iStent inject Trabecular Micro-Bypass device. It also initiated patient enrolment of key U.S. pivotal clinical studies for iDose Travoprost and iStent Infinite. Through continued investment and a new pharmaceutical development agreement with D. Western Therapeutic Institute Glaukos expanded its pharmaceutical capabilities. A strong pipeline is indicative of brighter prospects ahead. Management is optimistic about the recent Avedro buyout. The company outperformed the industry year-to-date. With respect to quarterly results, Glaukos exited the second quarter on a tepid note. Also, Glaukos faces cutthroat competition in the Medical Devices space. Further, an overtly stringent regulatory-approval process for the iDose platform is concerning." (9/12/2019) 2. BTIG Research analysts commented, "We maintain our Neutral rating on GKOS shares following a solid 1Q19 beat. Largely expected, GKOS delivered rev. of $54.0M vs. BTIG/Street est. of $49.7M/$50.2M as iStent inject conversions and OUS strength drove upside while competitive trialing was modest (below mgmt.’s initial expectations). CyPass share gains continue to buoy US results (we est. $9M-$10M/qtr.) Current business execution, market dynamics, and pricing all appear to be in-line to slightly better than originally guided with no material change to pipeline timelines. Against a ~$4M beat, mgmt. moved the lower-end of guidance up $5M (+$2.5M at the midpoint), sticking with a conservative (but optimistic) tone through the balance of the year. Mgmt. remains cautious around an increase in competitive trialing within the US combined with continued OUS challenges in the UK stemming from reimbursement cuts." (5/10/2019) Has Glaukos been receiving favorable news coverage? News coverage about GKOS stock has trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Glaukos earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Glaukos. Who are some of Glaukos' key competitors? Some companies that are related to Glaukos include ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Nevro (NVRO), ICU Medical (ICUI), Cantel Medical (CMD), Irhythm Technologies (IRTC), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP) and Cardiovascular Systems (CSII). What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include PTC Therapeutics (PTCT), Alibaba Group (BABA), Paypal (PYPL), Twilio (TWLO), NVIDIA (NVDA), Caterpillar (CAT), Baidu (BIDU), Splunk (SPLK), Boeing (BA) and Coupa Software (COUP). Who are Glaukos' key executives? Glaukos' management team includes the folowing people: Mr. Thomas William Burns, CEO, Pres & Director (Age 58)Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)Mr. Richard L. Harrison, Advisor (Age 62)Dr. Mory Gharib Ph.D., Co-Founder When did Glaukos IPO? (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Glaukos' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Interwest Venture Management Co. (2.78%), Peregrine Capital Management LLC (1.14%), Rhenman & Partners Asset Management AB (0.65%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Valeo Financial Advisors LLC (0.01%) and Exchange Traded Concepts LLC (0.00%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos. Which major investors are selling Glaukos stock? GKOS stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra and Joseph E Gilliam. View Insider Buying and Selling for Glaukos. Which major investors are buying Glaukos stock? GKOS stock was purchased by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, Exchange Traded Concepts LLC, Zurcher Kantonalbank Zurich Cantonalbank and Valeo Financial Advisors LLC. View Insider Buying and Selling for Glaukos. How do I buy shares of Glaukos? Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Glaukos' stock price today? One share of GKOS stock can currently be purchased for approximately $57.09. How big of a company is Glaukos? Glaukos has a market capitalization of $2.08 billion and generates $181.28 million in revenue each year. The medical instruments supplier earns $-12,950,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Glaukos employs 437 workers across the globe.View Additional Information About Glaukos. What is Glaukos' official website? The official website for Glaukos is http://www.glaukos.com/. How can I contact Glaukos? Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected] MarketBeat Community Rating for Glaukos (NYSE GKOS)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 365 (Vote Outperform)Underperform Votes: 275 (Vote Underperform)Total Votes: 640MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: What is Green Investing?
